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Chemokines and their receptors have key roles in cancer progression. The present
study investigated chemokine activity in the prostate cancer bone metastasis
microenvironment. Growth and migration of human prostate cancer cells were
assayed in cocultures with bone stromal cells. The migration of LNCaP cells signifi-
cantly increased when co-cultured with bone stromal cells isolated from prostate
cancer bone metastases. Cytokine array analysis of conditioned medium from bone
stromal cell cultures identified CCL5 as a concentration-dependent promoter of
LNCaP cell migration. The migration of LNCaP cells was suppressed when C-C motif
ligand 5 (CCL5) neutralizing antibody was added to cocultures with bone stromal
cells. Knockdown of androgen receptor with small interfering RNA increased the
migration of LNCaP cells compared with control cells, and CCL5 did not promote
the migration of androgen receptor knockdown LNCaP. Elevated CCL5 secretion in
bone stromal cells from metastatic lesions induced prostate cancer cell migration by
a mechanism consistent with CCL5 activity upstream of androgen receptor
signaling.
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1 | INTRODUCTION
Prostate cancer is among the most frequently diagnosed malignan-
cies in men worldwide.1 Skeletal metastases occur in approximately
80% of patients with advanced prostate cancer, for which there is
no curative treatment.2,3 Within the tumor microenvironment,
chemokines and their receptors influence growth and metastasis.4,5
For example, C-C motif ligand 2 (CCL2) is present in the microenvi-
ronment of many cancers and upregulated in prostate cancer cells.6
We previously reported that bone stromal cells and SaOS-2 osteo-
blast-like cells promoted prostate cancer metastasis through activa-
tion of transforming growth factor (TGF)-b1,7 and that CCL2, CCL4
and CCL22 were associated with prostate cancer progression.8-11
Upregulation of CCL5, a high-affinity ligand of CCR5, can increase
the aggressive potential of breast cancer cells12 and increase the
invasiveness of prostate cancer cells.13,14 CCL5-associated increase
in the size of prostate cancer stem cell populations and the meta-
static potential of prostate cancer cells have been found to involve
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androgen receptor (AR) signaling.15,16 CCL5 has been shown to
mediate prostate cancer progression, but the interactions of CCL5,
bone stromal cells and prostate cancer cells in the microenvironment
of bone metastases have not been determined.
In this study, bone stromal cells promoted prostate cancer pro-
gression through the secretion of CCL5. In vitro co-culture of bone
stromal cells with prostate cancer cells induced the expression of
CCL5, which promoted prostate cancer cell migration. CCL5 was
found to have a key role in the progression of prostate cancer in the
bone metastasis microenvironment.
2 | MATERIALS AND METHODS
2.1 | Reagents and antibodies
Recombinant human CCL5 (278-RN-050CF) was purchased from
R&D Systems (Minneapolis, Minnesota, USA). The primary antibodies
used in western blot and immunohistochemistry (IHC) assays
included rabbit anti-CCR5 (ab32048; Abcam, Cambridge, Mas-
sachusetts, USA), anti-AR (sc-7305; Santa Cruz Biotechnology, Dal-
las, Texas, USA) and anti-GAPDH (NB300-221; Novus Biologicals,
Littleton, Colorado, USA). MAB-678 antihuman CCL5 monoclonal
neutralizing antibody was obtained from R&D Systems. Normal rab-
bit IgG (sc-2027) used as a control in the CCL5 neutralizing antibody
assay was obtained from Santa Cruz Biotechnology.
2.2 | Cell culture
LNCaP and PC-3 human prostate cancer cell lines were purchased
from the American Type Culture Collection (Manassas, Virginia,
USA). Human SaOS-2 osteosarcoma cells were purchased from the
European Collection of Cell Cultures (Salisbury, UK). The LNCaP-SF
androgen-independent LNCaP cell line was established in our labora-
tory by long-term subculture of the parental LNCaP cells in RPMI
(Thermo Fisher Scientific, Waltham, Massachusetts, USA) with 5%
charcoal-stripped FBS (CCS; Hyclone, Logan, Utah, USA) and 1%
penicillin/streptomycin (Invitrogen, Carlsbad, California, USA).17
Bone-derived stromal cells (BDSC) and bone metastasis stromal cells
(BmetSC) were obtained from normal eleventh ribs and left thigh
bones with prostate cancer metastases as previously described.7 The
bone stromal cells were cultured in RPMI supplemented with 1%
penicillin/streptomycin and 10% FBS (Sigma-Aldrich, St. Louis, Mis-
souri, USA). LNCaP and PC-3 cells were cultured in RPMI supple-
mented with 5% FBS and 1% penicillin/streptomycin. SaOS-2 cells
were cultured in RPMI supplemented with 1% penicillin/strepto-
mycin and 5% FBS. All cells were kept at 37°C in a humidified atmo-
sphere with 5% CO2.
2.3 | Conditioned medium
Cells were seeded into 6-well culture plates and allowed to adhere
overnight. The next day, the medium was aspirated and replaced
with 2 mL of medium containing 5% FBS. The supernatant was
removed 48 hours later, centrifuged at 300 g for 10 minutes and
collected as conditioned medium (CM).
2.4 | Co-culture assays
Co-culture experiments were performed using Transwell cell culture
inserts (Greiner Bio-One, Monroe, North Carolina) in 6-well or 24-
well plates. Briefly, cells were added to the lower compartment and
allowed to attach for 12-24 hours. For the migration assay, cells
were placed into the upper compartment, the reagents were added
to the lower compartment and the plates were cultured for 24-
48 hours. For the proliferation assay, cells were placed into the
lower compartment and allowed to attach for 12-24 hours. Co-cul-
tured cells were then added to the upper compartment and the
plates were cultured for 24-72 hours.
2.5 | Cell migration assay
The cell migration assay was performed using 8.0 lm Transwell
inserts in 24-well culture plates. Prostate cancer cells were grown to
80% confluency in an appropriate medium. The cells were synchro-
nized by starvation in serum-free medium containing 0.5% BSA for
16 hours at 37°C in a humidified atmosphere with 5% CO2. Approxi-
mately 2-10 9 104 cells in 200 lL of culture medium supplemented
with 1% FBS (0.1% FBS for PC-3 cells) were placed in the upper
compartment. The lower compartment was filled with 600 lL of
medium containing 1% FBS (2.5% FBS for PC-3 cells). The cells were
allowed to attach for 2 hours, and then the lower compartment
medium was replaced with 600 lL of medium containing 5% FBS
with or without CCL5, or CM, or co-cultured cells, after washing the
wells twice with PBS. The cells on the upper surface of the Tran-
swell filter were removed carefully with a cotton swab and those on
the lower surface were fixed with 4% paraformaldehyde for 10 min-
utes, stained with 0.1% crystal violet for 15 minutes, and pho-
tographed. The crystal violet dye retained on the filters was
extracted into 33% acetic acid. Cell migration was measured by read-
ing the absorbance at 595 nm with correction at 450 nm on a
microplate reader, or microscopically assessed by counting stained
cells visually. Statistical analysis was performed using Student’s t-
test.
For the anti-CCL5 neutralizing antibody procedures, cancer cells
were seeded in the upper Transwell compartment with 1% FBS and
the lower compartment was filled with 5% FBS with or without anti-
CCL5 antibody at a concentration of 2 lg/mL and/or BmetSC. The
plates were incubated at 37°C and 5% CO2 for 48 hours.
2.6 | Western blot assay
Cell lysates were prepared with M-PER Mammalian Protein Extrac-
tion Reagent (Thermo Fisher Scientific). The soluble lysate (5-10 lg)
was mixed with LDS sample buffer and sample reducing agent and
was resolved by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis. The proteins were transferred to nitrocellulose
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membranes. The membranes were blocked with 1% gelatin in 0.05%
Tween in Tris-buffered saline for 1 hour at room temperature (RT)
and then incubated overnight at 4°C with anti-CCR5 and anti-AR
primary antibodies following the kit manufacturer’s instructions.
Membranes were washed 3 times before incubation with HRP-con-
jugated anti-rabbit secondary antibodies for 1 hour at RT. Protein
loading was determined with an anti-GAPDH control antibody. Pro-
tein bands were read using SuperSignal West Femto Maximum Sen-
sitivity Substrate (Thermo Fisher Scientific).
2.7 | Human cytokine antibody array
Cytokines were assayed in CM collected from LNCaP, BDSC and
BmetSC cell cultures using a Human Cytokine Array kit (ARY017,
R&D Systems) following the manufacturer’s instructions.
2.8 | ELISA
Human CCL5 secretion was measured in serum-free CM from
LNCaP, LNCaP-SF, BDSC, BmetSC and co-culture CM from BDSC or
BmetSC and LNCaP or LNCaP-SF using a Quantikine human ELISA
kit (DRN00B, R&D Systems), following the manufacturer’s instruc-
tions. Absorbance was measured at 450 nm and was corrected at
540 nm on a microplate reader. Statistical analysis was performed
using Student’s t-test.
2.9 | Knockdown of androgen receptor in LNCaP
cells
Androgen receptor-specific small interfering (si)RNA, siAR1
(HSS100619) and siAR2 (HSS179972) were synthesized by Thermo
Fisher Scientific. A validated nontargeting siRNA (Stealth RNAi
siRNA Negative Control Med GC Duplex #2) was also purchased
from Thermo Fisher Scientific. For AR knockdown, LNCaP cells were
plated into 6-well plates at 1 9 105 cells/well before transfection
with 10 n mol L1 of siRNA for 24 hours. Total proteins were
extracted at 0, 24, 48, 72 and 96 hours after transfection.
2.10 | Tissue microarray analysis
A human prostate cancer TMA (PR2085b) was purchased from US
Biomed (Rockville, MD). A TMA plate contained 20 cores of nor-
mal prostate tissue, 184 cores of prostate cancer tissue, and
4 cores of urothelial cancer. IHC staining was performed with an
EnVision Detection System Peroxidase/DAB+ Kit (K5007) following
the manufacturer’s protocol (Dako, Glostrup, Denmark) as previ-
ously described by Shin et al18 Microwave antigen retrieval was
performed in Dako Target Retrieval Solution for 10 minutes. The
arrays were evaluated by a pathologist blinded to the experimen-
tal procedures, and the intensities of the stained epithelial cells
were recorded as: , negative; +, weak; ++, moderate; or +++,
strong. Statistical analysis was performed using the v2-test for
trend.
3 | RESULTS
3.1 | SaOS-2 cells promoted migration of androgen
receptor-positive human prostate cancer cells;
androgen receptor-positive human prostate cancer
cells inhibited migration of SaOS-2 cells
As most prostate cancer bone metastases are osteoblastic, the SaOS-2
osteoblast-like cell line was used in the co-culture experiments. When
the AR-positive LNCaP and LNCaP-SF cells were co-cultured with
equal numbers of SaOS-2 cells, migration was significantly increased
(Figure 1A,B). However, increasing the number of co-cultured SaOS-2
cells to twice that of the prostate cancer cells did not further promote
the migration of LNCaP and LNCaP-SF cells (Figure 1A,B). Increase in
the number of osteoblasts may, thus, not be needed to promote the
migration of AR-positive metastatic prostate cancer cells within the
tumor microenvironment. Co-culture with SaOS-2 cells did not
increase the migration of AR-negative PC-3 cells (Figure 1C) or the
proliferation of prostate cancer cells regardless of AR status for up to
72 hours (Figure 1D-F). AR-positive prostate cancer cells significantly
inhibited the migration of SaOS-2 cells (Figure 1G), but AR-negative
PC-3 cells did not influence SaOS-2 migration (Figure 1H). AR-positive
prostate cancer cells may remain near, and promote changes in, osteo-
blasts. The study results are consistent with previous in vivo findings
that AR-positive and AR-negative prostate cancer cells formed
osteoblastic and osteolytic lesions, respectively.7,17
3.2 | Co-culture increased migration of both bone
stromal and androgen receptor-positive human
prostate cancer cells
Bone-derived stromal cells were co-cultured with LNCaP cells to inves-
tigate their interactions in the tumor microenvironment,7 and their
effect on the progression of osteoblastic bone metastasis. LNCaP
migration was significantly increased by both BDSC and BmetSC; the
effect of BmetSC was much stronger than that of BDSC (Figure 2A).
LNCaP cells significantly increased BDSC migration but significantly
decreased BmetSC migration (Figure 2B,C). The results suggest that
prostate cancer cells initially activated stromal cells, leading to cancer
cell migration, and that they could subsequently inactivate stromal cells,
leading to inhibition of migration and re-initiation of proliferation.19
3.3 | Bone stromal cells secreted C-C motif ligand 5
A human cytokine antibody array including of CM from LNCaP,
BDSC and BmetSC cultures revealed that CCL5 was secreted by
both BDSC and BmetSC and that BmetSC secreted more CCL5 than
BDSC (Figure 3A). ELISA determined that the amount of CCL5 was
proportionate to the bone stromal cell effect on LNCaP migration
and that neither LNCaP nor LNCaP-SF increased CCL5 secretion by
bone stromal cells (Figure 3B). To confirm that CCL5 was the only
chemokine to induce LNCaP migration, LNCaP cells were cultured
with CM from BDSC and BmetSC cultures. LNCaP migration was
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increased in proportion to CCL5 concentration, as determined by
ELISA (Figure 3C).
3.4 | C-C motif ligand 5 promoted LNCaP migration
in a dose-dependent manner
C-C motif ligand 5, at concentrations of 0.5 to 5.0 ng/mL, increased
LNCaP migration in a dose-dependent manner (Figure 4A), but it did
not increase LNCaP cell proliferation (Figure 4B). Western blot
assays confirmed that CCL5 receptor was constitutively expressed in
LNCaP cells, not only in cultures with CCL5, but also in control cul-
tures with only FBS (Figure 4C). Inhibition of BmetSC-induced
LNCaP migration in cocultures including CCL5 neutralizing antibody
confirmed CCL5 as a cause of BmetSC-induced LNCaP migration.
(Figure 4D).
3.5 | C-C motif ligand 5 did not induce the
migration of LNCaP cells after androgen receptor
knockdown
C-C motif ligand 5 is known to inhibit AR nuclear translocation and to
downregulate androgen signaling in prostate cancer cells.15 Recent
studies clarified that downregulation of AR not only inhibited cell pro-
liferation but also promoted cell migration through epithelial-mesench-
ymal transition.9,15 To examine whether CCL5 acted upstream of AR
signaling, AR expression in LNCaP cells was silenced by siRNA. AR
protein expression in SiAR1 and SiAR2 cells was measured by western
blot. Both SiAR1 and SiAR2 cells expressed low AR levels for up to
96 hours after transfection (Figure 5A). SiAR1 inhibited proliferation
more strongly than SiAR2 (Figure 5B), suggesting that the effective-
ness of AR knockdown by SiAR1 was better than that by SiAR2. SiAR1
F IGURE 1 Cell migration and proliferation in co-cultures of SaOS-2 and prostate cancer cells. A, LNCaP, B, LNCaP-SF (4 9 104 cell/well)
and C, PC-3 (2 9 104 cells/well) were placed in 24-well plates with Transwell inserts and co-cultured with 4 9 104 or 8 9 104 SaOS-2 cells/
well (2 9 104 cells/well for PC-3 cells). Cell migration was assayed after 24 h by staining with 0.1% crystal violet and reading the absorbance
at 595 nm with correction at 450 nm with a microplate reader. D, LNCaP, E, LNCaP-SF and F, PC-3 cells (1 9 106 cells/well) were placed into
the lower Transwell compartment in 6-well plates, and SaOS-2 cells were placed on the inserts. After co-culture for 24-72 h, prostate cancer
cells were harvested and the cells were counted using a hemocytometer. G,H, SaOS-2 cells (4 9 104/well) were placed on Transwell inserts in
24-well plates and co-cultured with 4 9 104 cells/well of LNCaP, LNCaP-SF G, and PC-3 H, cells. Migration was assayed after 24 h by
staining with 0.1% crystal violet. Data are means  SD. All experiments are performed in triplicate. *P < .05, **P < .01
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cells were, thus, used in the migration assay. Although the migration of
SiAR1 cells was strongly promoted by AR knockdown as previously
shown (Figure 5C, control vs 0 g/mL), the addition of CCL5 no longer
promoted the migration of SiAR1 cells (Figure 5C).
3.6 | C-C motif ligand 5 expression was stronger in
prostate cancer than in normal prostate tissue
CCL5-CCR5 signaling in prostate cancer tissue was investigated by IHC
staining of CCR5 in TMA plates. Of 184 prostate cancer cores, 2 were
peeled off, and 14 diagnosed as Gleason pattern 1 prostate cancer
were removed because Gleason score of clinically significant prostate
cancer is scored from 6 to 10.20 The remaining 168 cores were evalu-
ated. Of 20 normal prostate tissues, 1 was peeled off and the remaining
19 cores were evaluated. IHC staining revealed a significant increase in
CCR5 expression in prostate cancer cells compared with epithelial cells
in normal prostate tissue (Figure 6), indicating that CCL5-CCR5 signal-
ing was increased in prostate cancer cells.
4 | DISCUSSION
The AR is a primary driver of prostate cancer progression, and it is
strongly expressed before development of castration resistance.21
F IGURE 2 Cell migration in co-cultures
of bone-derived stromal cells (BDSC) or
bone metastasis stromal cells (BmetSC) and
LNCaP cells. A, 8 9 104 LNCaP cells/well
were placed in Transwell inserts in 24-well
plates and co-cultured with 8 9 104 BDSC
or BmetSC cells/well. Cell migration was
assayed after 24 h. B, 2 9 104 BDSC
cells/well C, BmetSC were placed in
Transwell inserts in 24-well plates and co-
cultured with 2 9 104 LNCaP cells/well.
Cells migration was assayed at 24 h by
0.1% crystal violet staining. Data are
means  SD. All experiments are
performed in triplicate. *P < .05, **P < .01,
***P < .001
F IGURE 3 Identification and
quantification of secreted proteins that
induced prostate cancer migration. A, The
graph shows chemokine expression in
arrays comparing conditioned medium
(CM) from LNCaP cells, bone-derived
stromal cells (BDSC) and bone metastasis
stromal cells (BmetSC) cultures. Underline
indicates C-C motif ligand 5 (CCR5) spots.
The mean values of 2 spots are shown. B,
Prostate cancer cells were co-cultured with
or without BDSC or BmetSC for 24 h. Cell
culture inserts (1.0-lm pore size) and 24-
well plates were used, and CCL5 in the
CM was determined by ELISA. C,
10 9 104 LNCaP cells/well were cultured
in Transwell inserts in 24-well plate with
or without 92 diluted CM from BDSC or
BmetSC cultures and migration was
assayed at 24 h. Data are means  SD. All
experiments are performed in triplicate.
**P < .01, ***P < .001
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Androgen-sensitive prostate cancer cells tend to metastasize to
bone, with 80%-90% of distant metastases found in bone.22,23 Once
in bone, prostate cancer cells interact with a variety of cells, mainly
bone stromal cells, and activate osteoblasts, resulting in formation of
osteoblastic lesions.24 Subsequently, prostate cancer cells in the
tumor microenvironment containing bone stromal cells and osteo-
blasts become migratory cells that are able to metastasize to other
sites.25 However, the mechanism of cancer cell activation in bone
metastatic lesions is not clear. Co-cultures of SaOS-2 cells and bone
stromal cells with prostate cancer cells found that both cell types
induced the migration of AR-positive cancer cells. Bone tissue is rich
in cytokines that are known to affect the behavior of cancer
cells.10,26 CCL5 was consistently secreted by BDSC and BmetSC
and, as previously shown,13 directly increased prostate cancer cell
F IGURE 4 Effect of the C-C motif ligand 5 (CCR5) -CCR5 axis on LNCaP cells. A, 8 9 104 LNCaP cells/well are placed in Transwell inserts
in 24-well plates with or without 0-5.0 ng/mL human recombinant CCL5 and cell migration was assayed at 48 h. B, 6 9 104 LNCaP cells/well
were placed in 6-well plates with or without 0-50 ng/mL human recombinant CCL5 for 24-48 h. Prostate cancer cells were harvested and the
cells were counted using a hemocytometer. C, CCR5 protein expression in LNCaP cells was assayed by western blot. LNCaP cells were
incubated in serum-free medium or 5% FBS with or without human recombinant 0-10 ng/mL CCL5 (upper panel). LNCaP cells were incubated
for 15 min to 24 h with or without 5 ng/mL human recombinant CCL5 (lower panel). D, 5 9 104 LNCaP cells/well were placed in Transwell
inserts in 24-well plate with CCL5 neutralizing antibody or normal rabbit IgG (2 lg/mL) or 5 9 104 BmetSC/well. Cells migration was assayed
by count at 48 h. Data are means  SD. All experiments were performed in triplicate. **P < .01, ***P < .001
F IGURE 5 Effect of the C-C motif ligand 5 (CCR5) -CCR5 axis on siAR LNCaP cells. A, 1 9 105 LNCaP cells/well were placed into 6-well
plates and transfected with 10 nmol L1 of SiAR1 or SiAR2 for 24 h. Total protein was extracted at 0, 24, 48, 72 and 96 h after transfection.
B, 1 9 105 LNCaP cells/well were plated into 6-well plates and transfected with 10 n mol L1 of SiAR1 or SiAR2 and cultured for 96 h. Cells
were harvested and counted at 0, 24, 48, 72 and 96 h after transfection using a hemocytometer. C, Control and SiAR1-transfected LNCaP
cells were placed in Transwell inserts (5 9 104 cells/well in 24-well plates) with 0-50 ng/mL human recombinant CCL5 and cell migration was
assayed at 48 h by counting. Data are means  SD. All experiments were performed in triplicate. ***P < .001
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migration but not proliferation. The study results are consistent with
those of Luo et al who found that upregulation of CCL5 expression
in bone marrow mesenchymal stem cells increased the metastatic
potential of prostate cancer cells, and that upregulation of CCL5
subsequently downregulated AR signaling, because of inhibition of
AR nuclear translocation.15 CCL5 has also been found to suppress
expression of prolyl hydroxylases and lead to suppression of VHL-
mediated HIF2a ubiquitination and suppression of AR signaling.16
AR signaling has been shown to promote proliferation and inhibit
migration of prostate cancer cells.9,27,28 The results obtained with
AR-silenced LNCaP cells indicate that CCL5 activity was located
upstream of AR signaling. Moreover, SaOS-2 did not promote the
migration of PC-3 AR-negative prostate cancer cells. These results
suggest that the migratory potential of AR-positive prostate cancer
cells in bone metastases was increased by CCL5 secreted by bone
stromal cells through the suppression of AR signaling. This novel
mechanism of the metastatic cascade is a potential target to prevent
secondary metastases. Expression of CCR5 and its receptor were
significantly higher in prostate cancer cells than in normal prostate
tissues, suggesting that CCL5 specifically acts on cancer cells. There-
fore, targeting CCR5 might be a novel treatment for prostate cancer
bone metastasis as well as CCL5. Furthermore, the CCL5-CCR5 axis
may be a novel biomarker for prostate cancer. The limitations of
using a prostate-specific antigen alone as a biomarker for prostate
cancer, and the need for more specific and effective biomarkers,
have been discussed elsewhere.29,30 Previously, we reported that
the serum CCL2 level in patients with prostate cancer was predictive
of the time taken by tumors to become castration-resistant and of
overall and prostate cancer-specific survival.31 Additional clinical evi-
dence is needed to show the superiority of the CCL5-CCR5 axis
over the CCL2-CCR2 axis as a prostate cancer biomarker.
There are some points to be discussed carefully in this study.
Chemokine array showed high intensity in IL-8 and CXCL12.
Although we did not focus on these chemokines because no signifi-
cant difference between BDSC and BmetSC were observed on array,
they may exert some effects on prostate cancer cells cooperating
with other functional molecules. For instance, CXCL12-mediated
activation of ERK or AKT pathways is modulated by PTEN status.32
Next, the effect of CCL5 is less than SiAR. As Figures 4A and 5C
show, the effect of CCL5 on migration was less than SiAR. More-
over, CCL5 could not inhibit LNCaP proliferation, as shown in Fig-
ure 4B. These results indicate that CCL5 can increase LNCaP
migration through inhibition of AR signaling, but its effect is not per-
fect: CCL5 cannot completely (only partially) inhibit AR signaling. In
contrast, because high concentration of CCL5 was reported to
increase prostate cancer proliferation, there may be different mecha-
nisms not associated with AR signaling.13
To our knowledge, this is the first study to show that CCL5 was
expressed in bone stromal cells and that the CCL5-CCR5 axis con-
tributed to prostate cancer cell migration. The CCL5-CCR5 axis, which
is activated in prostate cancer bone metastasis, may be a novel thera-
peutic target and a potential biomarker for prostate cancer.
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